# Leveraging the Gut Microbiome to Regulate Hepatic Gluconeogenesis

> **NIH NIH K08** · WEILL MEDICAL COLL OF CORNELL UNIV · 2022 · $169,884

## Abstract

Project Summary/Abstract:
The objective of this Mentored Clinical Scientist Career Development Award is to elucidate the underlying
mechanisms by which gut microbes regulate hepatic gluconeogenesis and thereby coordinate host nutrient
homeostasis in health and disease. Non-alcoholic fatty liver disease (NAFLD) is the most-prevalent chronic liver
disease worldwide and can progress to cirrhosis and liver cancer. The absence of approved pharmaceutical
treatments for NALFD identifies a significant unmet need. Whereas the gut microbiome contributes to NAFLD,
the underlying mechanisms are incompletely defined. Our published and preliminary data demonstrate that gut
microbes play a key role in regulating hepatic gluconeogenesis through portal vein metabolites, providing a clear
rationale for this research. We propose the central hypothesis that specific biologically-active microbial
metabolites are transported by the portal circulation to the liver, where they downregulate hepatic
gluconeogenesis in health, and that ultra-processed western diets disrupt this pathway to contribute to the
excess glucose production observed in NAFLD. Specific Aim 1 will identify the specific microbes and downstream
metabolites that regulate hepatic gluconeogenesis. Mice will be colonized with defined microbial consortia and
in vivo glucose production assays and in vitro primary mouse hepatocyte cultures will determine the specific
microbial metabolic components that control hepatic glucose production. Mice with diet-induced hyperglycemia
and NAFLD will be colonized with specific microbes or administered metabolites to restore normal hepatic
gluconeogenesis. Specific Aim 2 will define the maladaptive changes in gut microbiome function that contribute
to excess hepatic gluconeogenesis in human NAFLD. Donor stool from patients with NAFLD and controls will
be used to create mice with humanized gut microbiomes. Portal vein serum metabolomics and microbial whole
genome sequencing will be used to identify microbes and microbial-metabolites that contribute to excess hepatic
gluconeogenesis in human NAFLD. This research is significant because it will identify novel mechanisms by
which the microbial component of the gut-liver axis regulates hepatic gluconeogenesis in health and disease.
This research project will be performed in the context of a comprehensive career development plan that will
permit the investigator to acquire expertise in metabolomics, microbiome engineering, and bioinformatics
analysis. The work will be conducted at Weill Cornell Medical College, which together with The Rockefeller
University and Memorial Sloan Kettering Cancer Center constitutes the highly stimulating Tri-Institutional
research network. Seminars and specialized coursework will augment tailored guidance from the candidate’s
co-mentors, as well as from a distinguished advisory committee with complementary expertise. The candidate’s
ultimate goal is to become an independent investigator whose resear...

## Key facts

- **NIH application ID:** 10449804
- **Project number:** 1K08DK129867-01A1
- **Recipient organization:** WEILL MEDICAL COLL OF CORNELL UNIV
- **Principal Investigator:** Tibor Krisko
- **Activity code:** K08 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $169,884
- **Award type:** 1
- **Project period:** 2022-08-15 → 2027-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10449804

## Citation

> US National Institutes of Health, RePORTER application 10449804, Leveraging the Gut Microbiome to Regulate Hepatic Gluconeogenesis (1K08DK129867-01A1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10449804. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
